Dominick BossÃ©

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8613761/publications.pdf

Version: 2024-02-01

59 papers	2,474 citations	471061 17 h-index	233125 45 g-index
62 all docs	62 docs citations	62 times ranked	5198 citing authors

#	Article	IF	Citations
1	Attitudes towards openâ€label versus placeboâ€control designs in oncology randomized trials: A survey of medical oncologists. Journal of Evaluation in Clinical Practice, 2022, , .	0.9	2
2	Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews. Drugs, 2022, , .	4.9	3
3	Outcomes of second-line therapies in patients with metastatic de novo small cell prostate cancer (SCPC) and treatment-emergent neuroendocrine prostate cancer (tNEPC).. Journal of Clinical Oncology, 2022, 40, e17022-e17022.	0.8	0
4	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. European Urology Oncology, 2020, 3, 372-381.	2.6	59
5	Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence. Annals of Surgical Oncology, 2020, 27, 3683-3691.	0.7	13
6	Potential insights from population kinetic assessment of progression-free survival curves. Critical Reviews in Oncology/Hematology, 2020, 153, 103039.	2.0	3
7	A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model. Critical Reviews in Oncology/Hematology, 2020, 148, 102896.	2.0	10
8	Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. JCO Global Oncology, 2020, 6, 293-306.	0.8	4
9	Evolution in upfront treatment strategies for metastatic RCC. Nature Reviews Urology, 2020, 17, 73-74.	1.9	9
10	Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 863-868.	1.1	4
11	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Canadian Urological Association Journal, 2020, 15, 84-97.	0.3	11
12	The role of an open-label non-intervention design versus a placebo-control arm in oncology randomized trials.. Journal of Clinical Oncology, 2020, 38, e14099-e14099.	0.8	0
13	Response of Primary Renal Cell Carcinoma to Systemic Therapy. European Urology, 2019, 76, 852-860.	0.9	9
14	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications, 2019, 10, 4346.	5.8	139
15	The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity. Medical Oncology, 2019, 36, 18.	1.2	6
16	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2019, 20, 581-590.	5.1	124
17	Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and 99mTc-MDP Bone Scan in a Prospective Clinical Trial. Kidney Cancer, 2019, 3, 241-251.	0.2	2
18	Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic. Canadian Urological Association Journal, 2019, 14, E154-E158.	0.3	15

#	Article	IF	Citations
19	Radiogenomics in renal cell carcinoma. Abdominal Radiology, 2019, 44, 1990-1998.	1.0	37
20	Population kinetics of progression free survival (PFS).. Journal of Clinical Oncology, 2019, 37, e18251-e18251.	0.8	1
21	Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. Journal of Clinical Oncology, 2019, 37, 568-568.	0.8	3
22	Genomic and clinical determinants of recurrence in localized clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2019, 37, 664-664.	0.8	0
23	Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer.. Journal of Clinical Oncology, 2019, 37, e16501-e16501.	0.8	0
24	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. British Journal of Cancer, 2018, 118, 1238-1242.	2.9	33
25	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer Immunology Research, 2018, 6, 402-408.	1.6	56
26	Evaluation of diseaseâ€free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trialâ€level metaâ€analysis. Cancer, 2018, 124, 925-933.	2.0	38
27	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359, 801-806.	6.0	898
28	Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2018, 36, 3615-3623.	0.8	65
29	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer, 2018, 119, 707-712.	2.9	28
30	Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factorâ€"Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clinical Cancer Research, 2018, 24, 4081-4088.	3.2	24
31	Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. , 2018, 6, 5.		200
32	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Nonâ€"Clear Cell Renal Cell Carcinoma. Cancer Immunology Research, 2018, 6, 758-765.	1.6	89
33	Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis.. Journal of Clinical Oncology, 2018, 36, 4579-4579.	0.8	4
34	Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS).. Journal of Clinical Oncology, 2018, 36, 6556-6556.	0.8	1
35	Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2018, 36, 607-607.	0.8	12
36	Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 626-626.	0.8	1

#	Article	IF	Citations
37	Comparison of tumor mutational burden (TMB) in PBRM1/BAP1-based subsets of advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2018, 36, 634-634.	0.8	1
38	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. Journal of Clinical Oncology, 2018, 36, 667-667.	0.8	0
39	Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis.. Journal of Clinical Oncology, 2018, 36, 629-629.	0.8	0
40	Abstract 1644: Progression-free survival (PFS) as a surrogate for overall survival (OS). , 2018, , .		0
41	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunology Research, 2017, 5, 312-318.	1.6	354
42	P3.02c-073 Evidence Suggesting a Dichotomous â€œPresent vs absentâ€•Determinant of PDL1 Inhibitor Efficacy in Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, S1321.	0.5	0
43	Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Nonâ€“Lymph Node Distant Metastasis. Clinical Genitourinary Cancer, 2017, 15, e1089-e1094.	0.9	3
44	Pan-urologic cancer genomic subtypes that transcend tissue of origin. Nature Communications, 2017, 8, 199.	5.8	49
45	Immunotherapy in the Elderly. European Urology Focus, 2017, 3, 403-412.	1.6	16
46	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. , 2017, 5, 66.		37
47	Abstract 1774: Progression-free survival curves suggest a dichotomous determinant of PD-L1 inhibitor efficacy. , 2017, , .		2
48	Evaluation of disease-free survival as an intermediate metric for overall survival in localized renal cell carcinoma: A trial-level meta-analysis.. Journal of Clinical Oncology, 2017, 35, 4585-4585.	0.8	1
49	Evaluating the impact of bone-targeted agents in the era of novel androgen targeted therapy for metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2017, 35, e16500-e16500.	0.8	0
50	PROSPECT Eligibility and Clinical Outcomes: Results From the Pan-Canadian Rectal Cancer Consortium. Clinical Colorectal Cancer, 2016, 15, 243-249.	1.0	29
51	Does absolute gain in progression-free survival (PFS) half-life (tÂ½) translate into absolute overall survival (OS) benefit?. Journal of Clinical Oncology, 2016, 34, e18135-e18135.	0.8	0
52	PROSPECT eligibility and clinical outcomes: Results from the pan-Canadian rectal cancer consortium.. Journal of Clinical Oncology, 2015, 33, 6594-6594.	0.8	0
53	Measurement of Fractional Order Model Parameters of Respiratory Mechanical Impedance in Total Liquid Ventilation. IEEE Transactions on Biomedical Engineering, 2012, 59, 323-331.	2.5	24
54	Total liquid ventilation efficacy in an ovine model of severe meconium aspiration syndrome. Critical Care Medicine, 2011, 39, 1097-1103.	0.4	30

#	Article	IF	Citations
55	Clinician-Scientist Trainee: A German Perspective. Clinical and Investigative Medicine, 2011, 34, 324.	0.3	10
56	Scientific overview: CSCI-CITAC annual general meeting and young investigatorâ€™s forum 2010. Clinical and Investigative Medicine, 2011, 34, 105.	0.3	0
57	Experimental Validation of Cardiac Index Measurement Using Transpulmonary Thermodilution Technique in Neonatal Total Liquid Ventilation. ASAIO Journal, 2010, 56, 557-562.	0.9	4
58	Neonatal total liquid ventilation: is low-frequency forced oscillation technique suitable for respiratory mechanics assessment?. Journal of Applied Physiology, 2010, 109, 501-510.	1.2	6
59	Survol du programme scientifique du congrÃ¨s annuel de la SCRC-ACCFC 2009. Clinical and Investigative Medicine, 2010, 33, 73.	0.3	1